ORIGINAL INVESTIGATION. Headache Evaluation and Treatment by Primary Care Physicians in an Emergency Department in the Era of Triptans

Similar documents
Migraine Diagnosis and Treatment: Results From the American Migraine Study II

The Economic and Social Impact of Migraine Key Words

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:

Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches

An Expert System for Headache Diagnosis: The Computerized Headache Assessment Tool (CHAT) Morris Maizels, MD; William J.

...SELECTED ABSTRACTS...

Current Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN

Overuse of barbiturate and opioid containing medications for primary headache disorders Description

MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache

Measure Components Numerator Statement

11. HEADACHE 1. Pablo Lapuerta, MD, Steven Asch, MD, MPH, and Kenneth Clark, MD, MPH

MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache

A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN

10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.

PREVALENCE BY HEADACHE TYPE

Paediatric headaches. Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services. Brevity, levity, repetition

Regulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1).

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary

By Nathan Hall Associate Editor

Migraine headache is one of the

Clinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache.

Headache. Section 1. Migraine headache. Clinical presentation

MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache

ORIGINAL CONTRIBUTION. Efficacy and Safety of Acetaminophen, Aspirin, and Caffeine in Alleviating Migraine Headache Pain

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Migraine is a very common medical disorder

ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา

HEADACHES THE RED FLAGS

Inpatient Treatment of Status Migraine With Dihydroergotamine in Children and Adolescents

Migranal Nasal Spray. Migranal Nasal Spray (dihydroergotamine) Description

Update on Diagnosis and Management of Migraines

TABLE 1. Current Diagnostic Criteria for Migraine Without Aura 2 A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours

MIGRAINE A MYSTERY HEADACHE

OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES

Sumatriptan Injection (Imitrex / Alsuma / Sumavel / Zembrace)

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Outpatient Headache Care Guideline

Chronic Daily Headaches

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

HEADACHE 1 Pablo Lapuerta, M.D., and Steven Asch, M.D., M.P.H.

Psychiatric Comorbidity in Transformed Migraine: Presentation, Treatment, Impact and Outcome

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Daniel Kassicieh, DO, FAAN

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description

Migraine Management. Roger Cady, MD Headache Care Center Springfield, MO

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.

Strategies in Migraine Care

What is the Effectiveness of OnabotulinumtoxinA (Botox ) in Reducing the Number of Chronic Migraines (CM) in Patients Years Old?

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description

Migraine much more than just a headache

HEADACHE: Benign or Severe Dr Gobinda Chandra Roy

Single Use of Sumatriptan: A Patient Interview Study

Triptans Quantity Limit Program Summary

TREXIMET UTILIZATION MANAGEMENT CRITERIA

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

MIGRAINE ASSOCIATION OF IRELAND

Understanding. Migraine. Amy, diagnosed in 1989, with her family.

Index. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type.

How do we treat migraine? New SIGN Guidelines

My patient s pain in the head, is a pain in Greg Jicha, M.D., Ph.D.

Zonisamide for migraine prophylaxis in refractory patients

UNDERSTANDING CHRONIC MIGRAINE. Learn about diagnosis, management, and treatment options for this headache condition

Migraine is a primary headache disorder ... REPORTS... Migraine: Diagnosis, Management, and New Treatment Options

Is the Migraid device an asset in the non-pharmacologic treatment of migraine?

The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients

HEADACHE. Dr Nick Pendleton. September Headache

Headache Pain Generators

25/09/2018 HEADACHE. Dr Nick Pendleton

Maxalt. Maxalt / Maxalt-MLT (rizatriptan) Description. Section: Prescription Drugs Effective Date: April 1, 2016

ORIGINAL INVESTIGATION. Burden of Migraine in the United States

Risk Factors, Clinical Course, and Barriers to Care in Adults and Pediatrics. Rebecca R. Buttaccio, PA-C Dent Neurologic Institute

Migraine: Developing Drugs for Acute Treatment Guidance for Industry

ADVANCES IN MIGRAINE MANAGEMENT

Disclosures. Triptans for Kids 5/16/13

Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine

Diagnosis Isabelle Farrugia B.Pharm.(Hons.),M.S.(UIC) Completion of Assessment Questions following this article

Clinical Characteristics of Chronic Daily Headache Patients Visit to University Hospital

David W. Dodick M.D. Professor Director of Headache Medicine Department of Neurology Mayo Clinic Phoenix Arizona USA

Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.

ONZETRA XSAIL (sumatriptan) nasal powder

Migraine strikes study: factors in patients decision to treat early

Prevalence of headache in an elderly population: attack frequency, disability, and use of medication

Advances in the Treatment of Migraine

Classification of headaches

Coexistence of migraine and idiopathic intracranial hypertension without papilledema

Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE

Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine

An Overview of MOH. ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California

Headache ISSN

Painless, progressive weakness Could this be Motor Neurone Disease?

Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice

Tension-type Headaches

Controversy One: Headache and Disability. Robert Shapiro, MD, PhD University of Vermont

Disclosures. Objectives 6/2/2017

Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital

Transcription:

Headache Evaluation and Treatment by Primary Care Physicians in an Emergency Department in the Era of Triptans Morris Maizels, MD ORIGINAL INVESTIGATION Background: Despite advances in treatment, patients with migraine have been underdiagnosed and undertreated. Methods: Documentation of visits by patients with headache to an urgent care department staffed by primary care physicians was reviewed. Patients were also sent a brief headache screen, and those who replied were interviewed by telephone. Repeaters (patients who made 3 or more visits in 6 months) were excluded from chart review. Results: Over 6 months, 518 patients made 1004 visits to the emergency department for primary headache complaints: 464 patients (90%) made 1 or 2 visits (total visits, 502). A review of 174 charts documenting a diagnosis of migraine found that (1) the need for prophylaxis was determined in only 40 (31%) of the patients who were not already undergoing prophylaxis and (2) treatment in the emergency department was migraine specific in 46 patients (26%) or otherwise appropriate in 45 (25%). A review of 90 charts documenting nonmigraine diagnoses found that 30 patients (33%) had adequate history documented to exclude migraine as the diagnosis. Eighty-six patients (17%) were interviewed. An emergency department diagnosis of migraine (n=59) corresponded to a final diagnosis of migraine with (n=21) or without (n=18) medication overuse or chronic daily headache and/or transformed migraine with (n=18) or without (n=2) medication overuse. Discharge diagnoses that were not migraine (n=27) had final diagnoses of migraine with (n=9) or without (n=9) medication overuse or chronic daily headache/transformed migraine with (n=7) or without (n=2) medication overuse. Conclusions: In this emergency department population, many patients with migraine, chronic daily headache, or medication overuse are not accurately diagnosed. The need for prophylaxis is not usually assessed. Treatment is migraine specific in the minority of patients. Tension-type headache is rarely an accurate diagnosis in this emergency department population. Arch Intern Med. 2001;161:1969-1973 From the Department of Family Practice, Kaiser Permanente, Woodland Hills, Calif. ANNUALLY, more than 10% of the population experiences at least 1 migraine headache. 1 Migraine has a major economic impact 2 and strongly affects an individual s quality of life. 3 Despite significant disability, many patients with migraine remain undiagnosed. In a population-based survey, only 41% of women and 29% of men with migraine had ever had their migrane diagnosed by a physician. 4 Of patients with migraine who do present to a physician, only 45% to 51% receive a correct diagnosis. 5 Patients with chronic daily headache (4%-5% of adults) and drugrebound headache (1.5% of adults) may have severe disability as well. 6,7 Drugrebound headache is a daily headache sustained by the daily intake of analgesic agents or headache remedies. It is the most common reason for refractory headache. Drug-rebound headache has been coined an unrecognized epidemic. 8 Although most (54%) migraineurs first consult their family physician or internist, the next most common site for medical care is an emergency department (ED), accounting for 16% of first presentations. 9 Few articles have characterized the nature of care for patients with headache in the ED. In one study of a health maintenance organization over a 4-month period in 1991 and 1992, 152 patients made 323 ED visits for migraine: 36% of the patients made repeat visits, averaging 4.2 visits for migraine in the 4-month period. 10 Eighty-six percent of patients were treated in the ED with narcotics; 6% were given a discharge prescription for a migraine-specific compound (ergot or isometheptene compound); and 3% were given a prescription for a mi- 1969

PATIENTS AND METHODS PATIENTS Our medical group serves a large health maintenance organization with about 3 million members. The local facility serves a population of 160000. The urgent care department (UCD) is situated next to the ED; patients presenting with headache would be seen in the UCD between 7 AM and 10 PM daily and in the ED after hours. Approximately 245 patients are seen in the UCD daily. The UCD is staffed by 5 full-time UCD physicians and a mixture of approximately 20 per-diem physicians and 50 full-time primary care physicians. All physicians are board certified or board eligible in internal medicine or family practice. On a weekly basis, UCD notes were reviewed to identify patients who were discharged with a primary headache disorder (migraine, tension-type headache, or headache otherwise unspecified). Patients with associated febrile conditions or medical conditions that were likely to explain the headache (eg, sinus symptoms or uncontrolled hypertension) were excluded. Headaches due to recent trauma were excluded. Patients who were evaluated for worrisome headaches were also excluded. Emergency department (as opposed to UCD) notes were not reviewed because patients visiting the ED more commonly presented with worrisome headache syndromes. Chart review was limited to patients with fewer than 3 visits to the ED in 6 months (nonrepeaters). Charts of patients with 3 or more visits to the ED in 6 months (repeaters) were not reviewed because these patients were usually well known to the ED staff, usually presented with a request for narcotic injection, and typically received little evaluation. CHART REVIEW METHODS For patients diagnosed as having migraine, we reviewed the charts if there was documentation of migraine prophylaxis, and if not, documentation of headache frequency. Medications considered to be migraine prophylaxis included tricyclic antidepressant, any -blocker or calcium channel blocker, valproic acid, or gabapentin. Serotoninspecific reuptake inhibitors and other antidepressants were not considered migraine prophylactic agents. Appropriate reasons not to take prophylaxis included documented headache frequency of less than twice a month, documented lack of disability with headaches, failure with several prophylactic agents, or being followed by a neurologist. For patients diagnosed as having migraine, we also checked if the prescribed treatment (both in the ED and at home) was migraine specific, and if not, if there was a documented reason not to use migraine-specific therapy. specific treatment in the ED included any triptan or dihydroergotamine mesylate. Narcotics, parenteral nonsteroidal drugs (ketorolac tromethamine), and antiemetic agents were not considered migraine specific. Appropriate reasons for not using migraine-specific therapy included allergy to triptans; previous documented failure with such agents; unsuccessful use of triptan therapy for current headache episode; and contraindication to triptans because of a history of coronary artery disease or stroke, uncontrolled hypertension, or basilar or hemiplegic migraine. Relative contraindications were the presence of any 2 cardiac risk factors, including diabetes mellitus, hypertension, hyperlipidemia, smoking, age greater than 40 years for men or 50 years for women (or if no other risk factor was present, 50 years for men or 55 years for women). specific treatment at home included ergotamine products, Midrin (Carnrick Laboratories Inc, Cedar Knolls, NJ), triptans, and dihydroergotamine. Butalbital products, nonsteroidal antiinflammatory agents, and analgesic agents were not considered migraine specific. For patients diagnosed as having headache other than migraine, we determined whether the history was adequate to exclude migraine based on criteria of the International Headache Society 12 (Table 1). For all patients, we checked what physical examination was documented. Charts were reviewed for funduscopy and neurologic examination. An adequate neurologic examination was defined as any mention of cranial nerves and a motor response or deep tendon reflex examination. After the first 3 months of chart review, protocol was revised to allow further investigation, and all patients were mailed a brief headache survey. Patients who returned the survey were contacted by telephone by a trained interviewer to confirm a clinical diagnosis. If the diagnosis did not conform to International Headache Society criteria 12 for migraine, patients were diagnosed according to the revised criteria of Silberstein et al, 13 as having transformed migraine (history of episodic migraine, now with daily headache); chronic tension-type headache; and either of these with or without medication overuse (use of analgesic agents or headache remedies 3 d/wk). The study design was approved by the institutional review board. Informed consent was not required. graine prophylaxis ( -blockers, tricyclic agents, or calcium channel blockers). The introduction of sumatriptan in 1991 11 revolutionized the treatment of acute migraine. Our study sought to evaluate the nature of care of primary headache conditions in the ED in the triptan era. RESULTS Over 6 months, 518 patients made 1004 visits to the ED for primary headache complaints (Table 2): 426 patients (82%) made a single visit; 38 (7%) made 2 visits; and 54 (10%) made 3 or more visits (repeaters). Of all visits, 349 were to the UCD by nonrepeaters. From these 349 visits, 264 charts were available for review: 174 documented a discharge diagnosis of migraine, and 90 documented a nonmigraine headache diagnosis. Eleven patients not previously identified as having migraine were diagnosed by UCD physicians. All other diagnoses of migraine were in patients who had identified themselves as having migraine. Overall, the need for prophylaxis was determined in only 40 patients (31%) who were not already undergoing prophylaxis. Two patients were started on prophylactic 1970

Table 1. International Headache Society Criteria for Diagnosis of Migraine Without Aura* A. At least 5 attacks fulfilling B to D below. B. Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated). C. Headache has at least 2 of the following characteristics: 1. unilateral location 2. pulsating quality 3. moderate or severe intensity (inhibits or prohibits daily activities) 4. aggravation by walking stairs or similar routine physical activity D. During headache at least 1 of the following conditions exist: 1. nausea, vomiting, or both 2. photophobia and phonophobia E. No evidence of related organic disease. *Reproduced from the Cephalalgia, 1988, 12 with permission. Table 2. Distribution of Patients by Number of Visits to the Emergency Department During a 6-Month Period* Visit No. Category No. (%) of Patients treatment. Evaluation of physical examinations found documentation of funduscopic examination in 37 migraineurs (27%) and an adequate neurologic examination in 7 (5%). Table 3 summarizes the treatment of patients discharged with a diagnosis of migraine. Treatment in the ED was migraine specific for 46 patients (26%) or otherwise appropriate for 43 (25%). specific treatment in the ED was highly associated with a written prescription of a migraine-specific therapy. For the patients who received migraine-specific care in the UCD (n = 46), 25 (54%) received migraine-specific prescriptions for home use, of which 20 were for triptans. Only 1 patient in the group not given migraine-specific care in the UCD received a triptan prescription. The physician diagnoses of the 90 patients who were not diagnosed as having migraine are summarized in the tabulation below. Diagnosis by ED Physician No. of Patients Tension headache 67 Mixed 1 Allergy and/or sinus 2 Cervical radiculopathy 1 Hypertension 1 Viral 2 Anxiety and/or stress 3 Unspecified 13 No. (%) of Visits 1 Visit 426 (82) 426 (42) 2 Visits 38 (7) 76 (7) 2 Visits 54 (10) 502 (50) Total 518 (100) 1004 (100) *Total percentages may not be exact because of rounding. Range, 3 to 50 visits per patient; mean, 9.2 visits per patient. An adequate history to exclude migraine was documented in 30 (33%) records. Funduscopic examination was documented in 33 (37%) and an adequate neurologic examination in 8 (9%). Table 3. Treatment of Patients With Urgent Care Discharge Diagnosis of Migraine (n = 174)* Not Specific Treatment Type Specific None Urgent care 46 (26) 43 (25) 45 (26) 40 (23) treatment Prescriptions 39 (22) 37 (21) 26 (15) 72 (41) *All data represent number (percentage) of patients. Table 4. Urgent Care Diagnoses vs Diagnoses by Trained Telephone Interviewer* Urgent Care Diagnosis (n = 86) Telephone Diagnosis (n = 86) A brief headache survey was mailed to all 518 patients: 92 were returned, of which 86 responders were available for interview. Table 4 compares the UCD diagnoses with the clinical diagnoses made by a telephone interviewer. Tension-type headache without associated migraine or medication overuse was confirmed in only 1 patient. COMMENT Not Specific, Appropriate Undergoing Prophylaxis Previous studies of ED care for headache did not distinguish patients with frequent ED visits for headache (labeled as migraine) from patients who were infrequent users of ED resources. Our population sample of ED nonrepeaters was selected because one would expect these patients to receive an adequate, even if brief, evaluation in the ED. Furthermore, since the medical staff is composed of family physicians and internists, the documented care may reflect the care of patients with primary headache outside an ED setting. Yes Migraine, 59 Migraine, 39 10 28 Without MO, 18 6 12 With MO, 21 4 16 CDH/TM, 20 7 13 Without MO, 2 1 1 With MO, 18 6 12 Not migraine, 27 Migraine, 18 2 16 Without MO, 9 1 8 With MO, 9 1 8 CDH/TM, 9 3 6 Without MO, 2 0 2 With MO, 7 3 4 *All data represent number of patients. CDH indicates chronic daily headache; TM, transformed migraine; and MO, medication overuse. Data not entered by 1 patient. Includes 1 case of chronic tension-type headache. Includes 1 case of trigeminal neuralgia and 1 case of postconcussive headache. No 1971

S evere U ni- Table 5. Sample Evaluation for a Patient With Migraine Before Relief Medications Are Given* L ateral T hrobbing A ctivity (worsens headache) N ausea S ensitive to light and sound Mnemonic criteria for migraine based on International Headache Society criteria (Table 1). 12 Diagnosis of migraine requires 2 of the first 4 criteria, and 1 of the second 2 criteria. Migraine is episodic and usually lasts 4 to 72 hours. History 1. First or worst severe migraine headache? 2. Precipitated by exertion or trauma? 3. Any new symptoms? 4. Any decrease in alertness or awareness? 5. Unusual neck stiffness or neck pain? 6. Infrascapular or back pain? 7. Prior febrile illness? Physical Examination 1. Normal vital signs? 2. Normal fundi? 3. Normal speech and language function? 4. Problems with strength, coordination, or gait? *Adapted and reproduced from Headache Quarterly, 1992, 16 with permission. Of the charts for patients not diagnosed as having migraine, only 30 (33%) had adequate information to exclude migraine. That this is not just a documentation failure is confirmed by the patients who returned their headache surveys: 24 (89%) of 27 patients not diagnosed as having migraine were found to have either migraine (18 [67%]) or transformed migraine (6 [22%]), with or without medication overuse. Many cases of chronic daily headache occur in patients with a history of episodic migraine that has evolved into daily headache, so-called transformed migraine. 7 It seems, then, that many physicians are not familiar with the diagnostic criteria for migraine published by the International Headache Society 12 (Table 1) or the importance of recognizing transformed migraine and medication overuse. A simple mnemonic to aid in the diagnosis of migraine has been suggested (Figure). 14 More than half of the patients who were treated in the ED and were appropriate candidates received migraine-specific therapy in the ED. This figure is higher than it would be if the ED repeaters who were diagnosed as having migraine were included in the database. Absolute and relative contraindications to triptans, as well as the patient s previous experience with triptans, must be considered when judging whether the care is appropriate. specific care in the ED is strongly associated with an appropriate prescription for home care. All but 1 of the outpatient triptan prescriptions were given to patients who received migrainespecific care in the ED. Many patients who present to the ED with acute headache could benefit from prophylaxis. Migraine, similar to asthma, is a chronic disease with acute flares. Recognition of the need for prophylaxis is an important aspect of emergency care. Guidelines for migraine prophylaxis have been suggested. 15 A useful question may be, Do your headaches trouble you enough to take daily preventive medication? Chronic daily headache is important to recognize because it is most appropriately treated with prophylaxis rather than with immediate medication. Medication overuse or drug-rebound headache should be recognized because the headache will not improve until symptomatic treatment is stopped and an appropriate prophylaxis is administered. Failure to recognize drugrebound headache is an important reason for treatment failure. There are no agreed-on standards for the evaluation of patients with migraine in the ED. The approach of one headache expert is given in Table 5. 16 Findings from history review and physical examination are used to exclude worrisome causes of headache that may mimic migraine, and (juris)prudence would suggest a minimal evaluation of all patients with migraine. Although our UCD is staffed by primary care physicians, one cannot necessarily infer that the same level of care would occur in a primary care setting. Patients visit the ED for immediate relief rather than long-term management. However, for some patients the ED visit may be their only interaction with the health system for their headache disorder. CONCLUSIONS Our study of primary care physicians in an ED setting confirms previous studies showing that migraine is underdiagnosed and undertreated. Evaluation of these patients suggests that (1) most patients diagnosed as having migraine in the ED have transformed migraine; (2) most patients given nonmigraine diagnoses have migraine or transformed migraine; (3) medication overuse is common in ED patients with headache; (4) most ED patients with headache are not undergoing prophylaxis, even those who experience daily headache or consume analgesic agents daily; and (5) tension-type headache without medication overuse is rarely an accurate diagnosis in the ED. Physicians who work in urgent care settings have an important opportunity to improve the care of patients with primary headache disorders. Accepted for publication December 5, 2000. This study was supported by an education grant from Merck & Co Inc, West Point, Pa. The author is indebted to Raoul Burchette, MA, MS, for statistical support. An abstract of this article was presented at the 42nd Annual Scientific Meeting of the American Headache Society, Montreal, Quebec, June 24, 2000. 1972

Corresponding author and reprints: Morris Maizels, MD, Department of Family Practice, Kaiser Permanente, 5601 De Soto Ave, Woodland Hills, CA 91365-4084 (e-mail: Morris.Maizels@kp.org). REFERENCES 1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267:64-69. 2. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159: 813-818. 3. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA. 1989;262:907-913. 4. Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches: a comparison of symptom-based and reported physician diagnosis. Arch Intern Med. 1992;152:1273-1278. 5. Stang P, Osterhaus JT, Celentano DD. Migraine: patterns of healthcare use. Neurology. 1994;44(6, suppl 4):S47-S55. 6. Castillo J, Muñoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache. 1999;39:190-196. 7. Mathew NT. Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin. 1997;15:167-186. 8. Edmeads J. Analgesic-induced headaches: an unrecognized epidemic. Headache. 1990;30:614-615. 9. Osterhaus JT, Stang P, Yanagihara T, et al. Use of diagnostic procedures associated with incident migraine headaches among Olmstead County, MN residents 1979-1981 [abstract]. Abstr Int Soc Technol Assess Health Care. 1992; 28:57. 10. Kaa KA, Carlson JA, Osterhaus JT. Emergency department resource use by patients with migraine and asthma in a health maintenance organization. Ann Pharmacother. 1995;29:251-256. 11. Cady R, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of migraine attacks with sumatriptan. JAMA. 1991;265:2831-2835. 12. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalalgia. 1988;8(suppl 7):1-96. 13. Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near-daily headaches: proposed revisions to the IHS criteria. Headache. 1994; 34:1-7. 14. Maizels M. Teaching aids for primary care [letter]. Headache. 1999;39:522. 15. Capobianco DJ, Cheshire WP, Campbell JK. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clin Proc. 1996;71:1055-1066. 16. Moore KL. Emergency room treatment of migraine: the standard of care. Headache Q. 1992;3:91-96. 1973